Biomarker Validation in the Era of Precision Medicine
Biomarkers Are No Longer Optional in Drug Development A decade ago, biomarkers were an add-on to many clinical development programs: interesting, potentially informative, but rarely central to regulatory decision-making. That has changed. The growth of precision medicine, the expansion of companion diagnostic requirements, and the increasing use of biomarker-defined patient populations in oncology and rare […]